![]() ![]() Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. ![]() (AMAG) with a Zacks Rank #1 (Strong Buy). Kite Pharma currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.Ī better-ranked biomedical stock is AMAG Pharmaceuticals, Inc. (KITE) submitted an investigational new drug application to the FDA for KTE-C19 for refractory aggressive non-Hodgkin lymphoma. The move came on pretty good volume too with far more shares changing hands than in a. So make sure to keep an eye on this stock going forward to see if yesterday’s move higher lasts. (KITE) saw a big move last session, as the company’s shares fell by over 9 on the day. Over the last 30 days, this biopharmaceutical company witnessed one negative estimate revision and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. KITE closed at 63.07 on October 8 and was trading above the 20-day, 50-day. This also continues the recent uptrend of the company, as the stock is now up almost 60% in the past one-month time frame. This led to more shares changing hands than in a normal session. to develop cancer immunotherapy treatments. representative turnover intention: A growing concern in Bangladeshs pharmaceuticals industry. The upside was driven by a research collaboration and license agreement signed by the company with Amgen Inc. And, The Kite Runner is a tale of humans and humanity. Kite Pharma (KITE) announced that it has entered into a strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (KTE-C19) in Japan. (KITE) was a big mover last session with its shares rising over 15% on the day. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |